Abstract
Dünya Sağlık Örgütü tarafından 2020 yılı Mart ayında, solunum yolunu etkileyen SARS-CoV-2 virüsünün sebep olduğu koronavirüs hastalığı (COVID-19) nedeniyle pandemi ilan edildi. Ağır akciğer tutulumuyla seyreden bu enfeksiyon için komorbit hastalıklar tanımlandı. Çok faktörlü patofizyolojisi nedeniyle astım, en çok merak edilen, araştırılan ve komorbiditesi tartışmalı hastalıklardan birisi oldu. Gün geçtikçe kronik hastalıkların tedavisinde yeri önem kazanan ve kullanımı artan biyolojik ajanların, viral yükle ve hastalık semptomlarıyla ilişkisi ise araştırılmaktadır. Omalizumab astım ve kronik ürtikerde kullanım onayı olan insan kaynaklı anti immunglonulin E (IgE) antikorudur. Yirmi yaşında alerjik astım tanılı, bir yıldır omalizumab ile astım semptomları kontrol altında seyreden hastamızın COVID-19 hastalığı seyrini sunuyoruz. Hastamız öksürük veya diğer astım atak semptomları geliştirmeden, hastaneye yatırılmadan, COVID-19 hastalığını ayaktan geçirdi. Bu olgumuzu sunarak, COVID-19 hastalığı sırasında omalizumab tedavisinin hastalığın seyri üzerine etkisi olmadığını belirtmek istiyoruz.
Keywords
References
- Alberca R.W, Yendo T, Aoki V, et al. Asthmatic patients and COVID‐19: Different disease course? Allergy. 2021; 76(3): 963–5. doi: 10.1111/all.14601.
- Skevaki C, Karsonova A, Karaulov A, et al. Asthma-associated risk for COVID-19 development. J Allergy Clin Immunol. 2020; 146(6): 1295-1301. doi: 10.1016/j.jaci.2020.09.017.
- Türkiye Ulusal Allerji ve Klinik İmmünoloji Derneği Astım Tanı ve Tedavi Rehberi 2020 Güncellemesi ISBN: 978-605-74980-0-7
- Costa LDC, Costa PS, Camargos PAM. Exacerbation of asthma and airway infection: Is the virus the villain? J. Pediatr. 2014; 90: 542–555. doi: 10.1016/j.jped.2014.07.001.
- Wenzel SE. Complex phenotypes in asthma: current definitions. Pulm. Pharmacol. Ther. 2013; 26 (6): 710–5. doi: 10.1016/j.pupt.2013.07.003.
- Song J, Zeng M, Wang H, et al. Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19. Allergy. 2021; 76(2): 483-6. doi: 10.1111/all.14517.
- Kimura H, Francisco D, Conway M, et al. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. J. Allergy Clin. Immunol. 2020; 146 (1):80–8.e8. doi: 10.1016/j.jaci.2020.05.004.
- Zhou P, Yang X, Lou Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579 (7798): 270–3. doi: 10.1038/s41586-020-2012-7.
- Morais-Almeida M, Aguiar R, Martin B, et al. COVID-19, asthma, and biological therapies: What we need to know. World Allergy Organ J. 2020; 13(5): 100126. doi: 10.1016/j.waojou.2020.100126.
- Chipps BE, Lanier B, Milgrom H, et al. Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience. J Allergy Clin Immunol. 2017; 139(5): 1431-1444. doi: 10.1016/j.jaci.2017.03.002.
- Rogliani P, Calzetta L, Matera MG. Severe asthma and biological therapy: when which, and for whom. Pulm Ther. 2019; 6(1): 47-66. doi: 10.1007/s41030-019-00109-1.
- Gill MA, Liu AH, Calatroni A, et al. Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. J Allergy Clin Immunol. 2018; 141(5): 1735‐1743. doi: 10.1016/j.jaci.2017.07.035.
- Esquivel A, Busse WW, Calatroni A. Effects of omalizumab on rhinovirus infections, illnesses, and asthma exacerbations. Am J Respir Crit Care Med. 2017; 196(8): 985–992. doi: 10.1164/rccm.201701-0120OC.
Abstract
In March 2020, the World Health Organization declared a pandemic due to the coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus affecting the respiratory tract. Comorbid diseases with severe lung involvement were defined for this infection. Due to its multifactorial pathophysiology, asthma has become one of the most curious, researched, and controversial diseases with comorbidity. The relationship between viral load and disease symptoms of biological agents, which are becoming more important and increasingly used in treating chronic diseases, is being investigated. Omalizumab is a human anti-immunoglobulin E (IgE) antibody approved for asthma and chronic urticaria use. We present the course of COVID-19 disease in a 20-year-old patient with allergic asthma whose asthma symptoms were under control with omalizumab for one year. Our patient had an outpatient course for COVID-19 without developing a cough or other asthma attack symptoms and without hospitalization. By presenting this case, we would like to emphasize that omalizumab treatment during COVID-19 disease does not affect the course of the disease.
Keywords
References
- Alberca R.W, Yendo T, Aoki V, et al. Asthmatic patients and COVID‐19: Different disease course? Allergy. 2021; 76(3): 963–5. doi: 10.1111/all.14601.
- Skevaki C, Karsonova A, Karaulov A, et al. Asthma-associated risk for COVID-19 development. J Allergy Clin Immunol. 2020; 146(6): 1295-1301. doi: 10.1016/j.jaci.2020.09.017.
- Türkiye Ulusal Allerji ve Klinik İmmünoloji Derneği Astım Tanı ve Tedavi Rehberi 2020 Güncellemesi ISBN: 978-605-74980-0-7
- Costa LDC, Costa PS, Camargos PAM. Exacerbation of asthma and airway infection: Is the virus the villain? J. Pediatr. 2014; 90: 542–555. doi: 10.1016/j.jped.2014.07.001.
- Wenzel SE. Complex phenotypes in asthma: current definitions. Pulm. Pharmacol. Ther. 2013; 26 (6): 710–5. doi: 10.1016/j.pupt.2013.07.003.
- Song J, Zeng M, Wang H, et al. Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19. Allergy. 2021; 76(2): 483-6. doi: 10.1111/all.14517.
- Kimura H, Francisco D, Conway M, et al. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. J. Allergy Clin. Immunol. 2020; 146 (1):80–8.e8. doi: 10.1016/j.jaci.2020.05.004.
- Zhou P, Yang X, Lou Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579 (7798): 270–3. doi: 10.1038/s41586-020-2012-7.
- Morais-Almeida M, Aguiar R, Martin B, et al. COVID-19, asthma, and biological therapies: What we need to know. World Allergy Organ J. 2020; 13(5): 100126. doi: 10.1016/j.waojou.2020.100126.
- Chipps BE, Lanier B, Milgrom H, et al. Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience. J Allergy Clin Immunol. 2017; 139(5): 1431-1444. doi: 10.1016/j.jaci.2017.03.002.
- Rogliani P, Calzetta L, Matera MG. Severe asthma and biological therapy: when which, and for whom. Pulm Ther. 2019; 6(1): 47-66. doi: 10.1007/s41030-019-00109-1.
- Gill MA, Liu AH, Calatroni A, et al. Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. J Allergy Clin Immunol. 2018; 141(5): 1735‐1743. doi: 10.1016/j.jaci.2017.07.035.
- Esquivel A, Busse WW, Calatroni A. Effects of omalizumab on rhinovirus infections, illnesses, and asthma exacerbations. Am J Respir Crit Care Med. 2017; 196(8): 985–992. doi: 10.1164/rccm.201701-0120OC.
Details
| Primary Language | English |
|---|---|
| Subjects | Infectious Diseases, Clinical Sciences (Other) |
| Journal Section | Case Report |
| Authors | |
| Early Pub Date | May 19, 2024 |
| Publication Date | April 30, 2024 |
| Submission Date | November 24, 2023 |
| Acceptance Date | February 18, 2024 |
| Published in Issue | Year 2024 Volume: 8 Issue: 1 |
Dergimiz Uluslararası hakemli bir dergi olup TÜRKİYE ATIF DİZİNİ, TürkMedline, CrossREF, ASOS index, Google Scholar, JournalTOCs, Eurasian Scientific Journal Index(ESJI), SOBIAD ve ISIindexing dizinlerinde taranmaktadır. TR Dizin(ULAKBİM), SCOPUS, DOAJ için başvurularımızın sonuçlanması beklenmektedir.